Gain Therapeutics, Inc. — 2022 Form 10-K Summary
Business and reporting period. Gain Therapeutics is a pre-revenue biotechnology company developing small-molecule therapeutics using its licensed SEE-Tx platform to identify allosteric protein-binding sites. Its lead candidate, GT-02287, targets GBA1 Parkinson’s disease and related GCase disorders. This annual report covers the fiscal year ended December 31, 2022, with comparison to 2021; it does not provide standalone fourth-quarter results.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $140,108 | $164,994 |
| Research and development expense | $8.38 million | $7.16 million |
| General and administrative expense | $9.54 million | $6.83 million |
| Operating loss | $17.78 million | $13.83 million |
| Net loss | $17.59 million | $13.89 million |
| Basic and diluted loss per share | $1.48 | $1.37 |
| Cash used in operating activities | $14.69 million | $12.37 million |
- Revenue was primarily collaboration revenue from Zentalis; Gain reported no product sales. Revenue was immaterial relative to operating expenses, so the filing does not present a meaningful operating margin.
- At December 31, 2022, cash and cash equivalents were $7.31 million and marketable securities were $14.77 million, or about $22.08 million combined, compared with $36.88 million in cash and cash equivalents at year-end 2021. Current assets were $21.09 million and current liabilities were $4.13 million.
- Loans totaled approximately $0.60 million at year-end 2022, down from $0.69 million a year earlier. Operating lease liabilities were approximately $0.67 million. The company reported no off-balance-sheet arrangements.
- Management estimated available cash, cash equivalents and marketable securities would fund operating and capital needs into the second quarter of 2024. This estimate is subject to assumptions and the company says additional financing will be needed.
Changes and notable items
- Net loss increased by $3.70 million year over year. R&D expense rose $1.21 million, reflecting advancement of the GBA1 Parkinson’s program, pre-IND work and higher personnel costs. G&A expense rose $2.71 million, including legal, audit, insurance, IT and personnel costs.
- Operating cash use increased by $2.33 million. Investing cash use was $14.77 million, mainly due to purchases of U.S. Treasury securities; these purchases shifted funds into marketable securities rather than representing equivalent operating burn.
- Gain selected GT-02287 as its candidate for GBA1-related diseases and retained GT-02329 as a potential backup, reducing projected GBA1 program development costs by approximately $8.4 million.
- Zentalis informed Gain during 2022 that it wanted to wind down their oncology collaboration. Gain planned to continue relevant research independently. Collaboration revenue was $132,640 in 2022, and $55,180 of deferred income remained at year-end.
Outlook, risks and contingencies
- Management expected to complete GT-02287 IND-enabling toxicology in the first half of 2023 and planned a first-in-human Phase 1 trial in Australia in the second half of 2023, initially assessing safety and pharmacokinetics in healthy volunteers. These were plans, not reported completed milestones.
- The company described encouraging preclinical findings, including increased GCase activity and improvements in disease-related biomarkers and animal-model measures. These results are not clinical evidence; Gain had not tested any product candidate in clinical trials as of the filing.
- Gain is streamlining operations and prioritizing Parkinson’s and Gaucher programs, while continuing earlier research in Krabbe disease, liver and lung disease, and oncology. It is seeking non-dilutive funding for other programs and remains open to partnerships.
- Principal risks include continued losses, uncertain clinical and regulatory outcomes, difficulty enrolling patients in rare-disease trials, dependence on the licensed SEE-Tx technology and third-party manufacturers and research providers, competition, intellectual-property exposure, and the need for additional capital. Financing may dilute shareholders or require the company to reduce programs or license rights.
- The company cited macroeconomic, geopolitical and supply-chain uncertainty, including inflation, higher interest rates, currency fluctuations, bank failures, the war in Ukraine and potential impacts on access to financing. It reported no legal proceedings.
- Financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; a previously reported material weakness was deemed remediated. The auditor did not provide an internal-control attestation.
- After year-end, the company announced a €1.2 million Eurostars/Innosuisse grant for an alpha-1 antitrypsin deficiency research project.
Important facts for investors to verify
- Whether the planned GT-02287 toxicology, regulatory submission and Phase 1 trial milestones were achieved, and what the clinical data show.
- Cash and marketable securities, quarterly cash burn, and the assumptions underlying the stated runway into Q2 2024; also assess available financing capacity under the shelf and at-the-market programs, which had not been used by year-end 2022.
- Whether Zentalis’s collaboration wind-down changed expected revenue, obligations or the resources required to continue the oncology program.
- The status and strength of patent applications and the company’s rights under the Minoryx license, including related-party terms and potential royalties.
- Whether the €1.2 million grant was received and the extent to which it funds the A1AT program without diverting resources from lead candidates.